Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up
Abstract Background Prevalence data of chronic hepatitis C virus (HCV) infection are needed to estimate the budgetary impact of reimbursement of direct-acting antivirals (DAAs). In Belgium, the restricted reimbursement criteria are mainly guided by regional seroprevalence estimates of 0.87% from 1993 to 1994. In this first Belgian nationwide HCV prevalence study, we set out to update the seroprevalence and prevalence of chronic HCV infection estimates in the Belgian general population in order to guide decisions on DAA reimbursement. Methods Residual sera were collected through clinical labora... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2019 |
Reihe/Periodikum: | BMC Public Health, Vol 19, Iss 1, Pp 1-7 (2019) |
Verlag/Hrsg.: |
BMC
|
Schlagwörter: | Hepatitis C / Prevalence / Chronic hepatitis C virus infection / Seroprevalence / Direct-acting antivirals / Belgium / Public aspects of medicine / RA1-1270 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28971140 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.1186/s12889-018-6347-z |